News Releases

Licensing

Licensing
Jul.19.2019
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with colorectal cancer (63.8KB)
Licensing
Jul.11.2019
ONO and Forty Seven, Inc. Sign a License Agreement to Develop, Manufacture and Commercialize 5F9 in Japan, South Korea, Taiwan and Other Selected Countries in Southeast Asia (65.5KB)
Licensing
Jun.25.2019
ONO Enters into Exclusive License Agreement with Rafael Pharmaceuticals on CPI-613 (devimistat), a Cancer Metabolism Inhibitor, and Other Related Compounds (40.5KB)
Licensing
Mar.27.2019
ONO Announces a Strategic Drug Discovery Alliance Agreement with Cancer Research UK and LifeArc for Cancer Immunotherapy (64.3KB)
Licensing
Mar.18.2019
Ono Enters into Research Collaboration Agreement with twoXAR, Inc. (37.5KB)
Licensing
Jan.31.2019
ONO Announces a Strategic Partnership Agreement with Repare Therapeutics for a Pol-theta Inhibitor Program (108KB)
Licensing
Sep.18.2018
ONO announces collaboration with Fate Therapeutics for two iPSC-derived CAR-T Therapies for Cancers (67.5KB)
Licensing
Aug.28.2018
Ono Enters into Collaboration Agreement on Combination Therapy of Opdivo® and Rubraca® with BMS and Clovis (69.1KB)
Licensing
Aug.22.2018
Ono and Takeda Initiate Clinical Collaboration on Combination Therapy of Opdivo® (Nivolumab) and Cabozantinib in Japan (75.4KB)
Licensing
Mar.14.2018
Ono Enters into New Collaboration Agreement with Merus N.V. (106KB)
Licensing
Dec.19.2017
ONO enters into Collaboration Agreement with Schrödinger Inc. (41.2KB)
Licensing
Dec.14.2017
ONO Enters into License Agreement with Bristol-Myers Squibb for Prostaglandin E2 Receptor Antagonists relating to Immuno-Oncology Programs (44.1KB)
Licensing
Dec.12.2017
Ono Enters into Collaboration Agreement with Cyclenium Pharma, Inc. (33.8KB)
Licensing
Nov.09.2017
ONO announces collaboration with Neurimmune in Neurodegenerative Diseases Field (59.7KB)
Licensing
Oct.12.2017
Ono Enters into Exclusive License Agreement with Karyopharm to Develop and Commercialize Selinexor and KPT-8602, XPO1 Inhibitors (77.9KB)
Licensing
Sep.08.2017
CONCLUSION OF DEVELOPMENT COLLABORATION AGREEMENT FOR OPDIVO® (NIVOLUMAB) AND LENVIMA® (LENVATINIB MESYLATE) COMBINATION THERAPY FOR TREATMENT OF HEPATOCELLULAR CARCINOMA (124KB)
Licensing
Sep.01.2017
Ono and Seikagaku Reach a Definitive Agreement Related to Co-development and Marketing Collaboration on SI-613 for the Treatment of Osteoarthritis in Japan (48.1KB)
Licensing
May.31.2017
ONO Concludes a License Agreement with Array Biopharma related to Binimetinib, a MEK inhibitor and Encorafenib, a BRAF inhibitor (59.8KB)
Licensing
May.12.2017
Seikagaku and Ono Reach a Basic Agreement Related to Co-development and Marketing Collaboration on SI-613 for the Treatment of Osteoarthritis in Japan (47.8KB)
Licensing
Mar.28.2017
ONO Enters into a Research and Option Agreement with Numab (42.6KB)
Licensing
Mar.21.2017
Ono Enters into Collaboration Agreement with X-Chem, Inc. (53.8KB)
Licensing
Jan.21.2017
Ono Pharmaceutical Company and Bristol-Myers Squibb Enter Settlement and License Agreement with Merck for Anti-PD-1 Antibody Patent Infringement Litigation (81.7KB)